Financial Performance - The group's revenue for the year ended December 31, 2022, was RMB 727.8 million, an increase of RMB 121.0 million or 19.9% compared to RMB 606.8 million for the year ended December 31, 2021, primarily driven by increased revenue from medical services and pharmaceutical sales[34]. - The company's profit increased by 33.3% from RMB 37.0 million in 2021 to RMB 49.3 million in 2022, with net profit margins improving from 6.1% to 6.8%[78]. - The group's consolidated revenue for the year ended December 31, 2022, was RMB 727.8 million, an increase of 19.9% compared to the previous year[123]. - Total revenue from treatment and comprehensive medical services was RMB 463.2 million, accounting for 63.6% of total revenue[138]. - Total revenue from drug sales was RMB 264.6 million, representing 36.4% of total revenue, up 23.4% from RMB 214.5 million in 2021[153]. - The company's gross profit increased by 2.3% from RMB 135.3 million for the year ended December 31, 2021, to RMB 138.4 million for the year ended December 31, 2022, while the gross profit margin decreased from 22.3% to 19.0%[164]. Patient Visits and Services - Total inpatient visits reached 50,920, an increase of 15.8% compared to 43,973 in the previous year[1]. - Outpatient visits totaled 1,286,815, reflecting an 8.7% increase from 1,183,408 in the previous year[1]. - The number of outpatient visits increased to 1,286,815 in 2022 from 1,183,408 in 2021, while the average outpatient fee rose from RMB 265.7 to RMB 312.7[73]. - Inpatient visits grew by 15.8% to 50,920 in 2022 compared to 43,973 in 2021[130]. - Total inpatient visits reached 50,920, representing a year-on-year growth of 15.8%[123]. - Outpatient visits increased by 8.7% to 1,286,815 in 2022 from 1,183,408 in 2021[130]. Costs and Expenses - Average inpatient cost decreased by 3.9% to RMB 6,385.2 from RMB 6,645.4 in the previous year[1]. - Average outpatient cost increased by 17.7% to RMB 312.7 from RMB 265.7 in the previous year[1]. - Employee costs for the fiscal year 2022 amounted to approximately RMB 193 million, an increase from RMB 173 million in the previous fiscal year, with a total of 1,847 full-time employees as of December 31, 2022[61]. - The group's sales costs rose by 25.0% to RMB 589.4 million, up from RMB 471.5 million in the previous year, primarily due to increased drug costs and employee benefits[112]. - The average length of hospital stay decreased by 9.4% to 9.6 days from 10.6 days year-on-year[130]. Cash Flow and Financial Position - The group reported a net cash generated from operating activities of RMB 118.5 million for the year ended December 31, 2022, compared to RMB 91.4 million in the previous year[57]. - The group's cash and cash equivalents totaled approximately RMB 255.2 million as of December 31, 2022, a slight decrease from RMB 263.6 million as of December 31, 2021[51]. - The company's net current liabilities decreased from RMB 65.4 million as of December 31, 2021, to RMB 44.2 million as of December 31, 2022, primarily due to cash inflows from operating activities[168]. - The company's total liabilities to total assets ratio was 40.7% as of December 31, 2022, compared to 41.1% as of December 31, 2021[176]. - Borrowings decreased from RMB 187.0 million as of December 31, 2021, to RMB 141.0 million as of December 31, 2022, a reduction of RMB 46.0 million[108]. Strategic Initiatives and Developments - The company has developed over ten management systems recognized by the Henan Provincial Department of Science and Technology, enhancing operational efficiency[30]. - The introduction of multidisciplinary treatment models (MDT) aims to improve patient care and address healthcare access issues[22]. - The company plans to expand its business through the acquisition of hospitals, with an allocation of HKD 69.2 million for this purpose, expected to be utilized by the end of 2023[63]. - The company aims to enhance its medical supply chain business and employee training, with a budget of RMB 16.7 million and RMB 13.3 million respectively, both expected to be utilized by the end of 2023[63]. - The company plans to strengthen clinical academic research and introduce advanced medical technologies to enhance service quality[136]. Social Responsibility and Community Engagement - The company actively participated in COVID-19 prevention efforts, including socialized nucleic acid testing and vaccination[23]. - The group emphasized the importance of social responsibility and community engagement through various health initiatives and free screenings[125]. - The group has engaged in various social welfare activities, including free lung nodule screenings for over 2,000 individuals and nearly 100 free medical consultation events during the reporting period[41].
宏力医疗管理(09906) - 2022 - 年度财报